TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 8-17~* BD type I or II comorbid with ADHD~* Baseline score in the YMRS \> or = 20~Exclusion Criteria:~* IQ \< 70~* Pharmacologic treatment in the last month~* Pregnancy or absence of a contraceptive method in fertile girls~* Diagnoses: pervasive development disorder, schizophrenia, drug abuse or dependency~* Risk of suicide or homicide~* Clinical condition that might interfere in the study~* Known sensibility to aripiprazole

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients aged ≥ 6 years and ≤ 65 years on the day informed consent is obtained~2. Patients diagnosed with TSC based on the clinical diagnostic criteria of International Tuberous Sclerosis Complex Consensus Conference 2012 and presenting visible facial angiofibroma~3. An FA severity score of 2 or 3 on the IGA scale~4. Patients or their legal representatives capable of understanding the explanation of the clinical trial and who give written informed consent for participation~5. Patients or their legal representatives able to maintain patient diaries following the instructions of the investigator or sub-investigator~Exclusion Criteria:~1. Patients who cannot carry out the treatment plan or follow-up assessment~2. Patients with serious skin lesions such as erosions or ulcers~3. Patients with known hypersensitivity to any component of the study product~4. Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrolment~5. Patients who received laser therapy or surgical therapy within 6 months prior to trial enrolment~6. Patients who participated in any other clinical trial within 3 months prior to the day of enrolment~7. Patients judged unsuitable for this clinical trial by the investigator or sub-investigator~8. Pregnant or lactating females~9. Sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception~10. Patients with immune dysfunction or receiving any form of immunosuppression~11. Patients with severe FA, with a score of 4 on the IGA scale~12. Patients with an FA severity score of less than 2 on the IGA scale

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.5% Rapamycin cream, topical (Type: EXPERIMENTAL): Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
- 1.0% Rapamycin cream, topical (Type: EXPERIMENTAL): Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo cream topical, applied once daily before bed on affected area for 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic unilateral stroke lesion (confirmed by the most recent clinical or radiological reports) at least 3 months prior to participation in this project.~* Paresis confined to one side, with moderate to severe motor impairment of the upper limb (Fugl-Meyer upper extremity scores of 10-40)~* Capacity to provide informed consent~Exclusion Criteria:~* Muscle tone abnormalities and motor or sensory impairment in the unimpaired limb~* Severe wasting or contracture or significant sensory deficits in the paretic upper limb~* Severe cognitive or affective dysfunction that prevents normal communication and understanding of consent or instruction~* Severe concurrent medical problems (e.g. cardiorespiratory impairment)~* Using a pacemaker~* Metal implants in the head~* Known adverse reaction to TMS and tDCS~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sham, Anodal, Cathodal (Type: EXPERIMENTAL): Treatment order 1: Sham, Anodal, Cathodal
- Anodal, Cathodal, Sham (Type: EXPERIMENTAL): Treatment order 2: Anodal, Cathodal, Sham
- Cathodal, Sham, Anodal (Type: EXPERIMENTAL): Treatment order 3: Cathodal, Sham, Anodal
- Sham, Cathodal, Anodal (Type: EXPERIMENTAL): Treatment order 4: Sham, Cathodal, Anodal
- Cathodal, Anodal, Sham (Type: EXPERIMENTAL): Treatment order 5: Cathodal, Anodal, Sham
- Anodal, Sham, Cathodal (Type: EXPERIMENTAL): Treatment order 6: Anodal, Sham, Cathodal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluoride Varnish for Treatment of White Spot Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* no systemic disease~* has completed fixed orthodontic treatment, brackets debonded~* has at least two teeth with whitre spot lesions~* has received conventional periodontal therapy after orthodontic tretament~Exclusion Criteria:~* presence of enamel hypoplasia or dental fluorosis~* presence of tetracycline pigmentation~* periodontal pocketing of 3mm or greater~* taking antibiotics~* presence of carious cavities~* allergy to fluoride gel / varnish being used in study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Pediagel (Type: ACTIVE_COMPARATOR): 1.23% Acidulated Phosphate Fluoride Gel
- 3M Vanish Varnish (Type: EXPERIMENTAL): 5% sodium fluoride varnish

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
KEY INCLUSION CRITERIA:~1. Male or female, ages 18 to 75 years.~2. History of GERD symptoms for at least 3 months immediately before screening.~3. Heartburn for at least 2 days a week for at least 1 month before screening.~4. Esophageal erosions of LA Grades C or D based on EGD taken within 14 days prior to enrollment.~5. Subjects who are H. pylori negative based on a screening test.~6. Females should be either of non-childbearing potential or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of contraception.~7. Subjects must be able to read, write, and understand the language of the symptom diary.~KEY EXCLUSION CRITERIA:~1. Current or a history of esophageal motility disorders.~2. Current or a history of Barrett's esophagus.~3. Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).~4. Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.~5. Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.~6. Inflammatory bowel disease.~7. Unstable diabetes mellitus.~8. History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.~9. Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral steroids (\>= 20 mg/day prednisone or equivalent), or aspirin (\> 325 mg/day).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects must be willing and able to give signed and dated written informed consent~* Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control~* Subjects should have been taking the same daily dose of metformin ≥ 1500 mg~* Fasting Plasma Glucose ≤ 270 mg/dL (≤15 mmol/L)~* Males and females, aged ≥18 years old at time of screening visit~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test~* WOCBP and males must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug~Exclusion Criteria:~* Clinical diagnosis of type I diabetes~* History of diabetic ketoacidosis~* Cardiovascular/vascular diseases within 3 months of the enrollment~* Renal disease~* Hepatic diseases~* History of, or currently, acute or chronic pancreatitis~* Hematological and oncological disease/conditions~* Patients who have contraindications to therapy being studied~* Patients on weight loss program(s)~* Replacement or chronic systemic corticosteroid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo (Type: EXPERIMENTAL): Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
- Glimepiride or Placebo (Type: EXPERIMENTAL): Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as advanced RCC after failure of one prior systemic therapy.~Exclusion Criteria:~* Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information.~* Patients with hypersensitivity to axitinib or to any other component of INLYTA® .~* Patients under 18.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients who are using Axitinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months~* Inadequate response or limiting side effects with pharmacotherapy for the treatment of OAB~Exclusion Criteria:~* Overactive Bladder caused by neurological condition~* Patient has predominance of stress incontinence~* History or evidence of pelvic or urological abnormality~* Prior use of BOTOX for any urological condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 100U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 100U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 300U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 300U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 400U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 400U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 500U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 500U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults~* ADHD diagnosis (any type: Combined, Predominantly Inattentive, or Predominantly Hyperactive-Impulsive)~* Patients with an Adult ADHD Investigator Symptom Rating Scale (AISRS) score greater than 24 at screening/baseline~* Ability to read and understand English~Exclusion Criteria:~* Any significant history of cardiovascular disease or cardiovascular disease detectable via ECG~* History of diagnosis of substance or alcohol dependence or admission/hospitalization for rehabilitation for dependence~* Current neurologic or psychiatric diagnosis that would make patient inappropriate for participation~* Anxiety assessments of moderate or severe~* Depression assessments of moderate or severe~* History or current suicidal thoughts or attempts~* Known allergies, hypersensitivity, or intolerance to OROS MPH

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
- 002 (Type: PLACEBO_COMPARATOR): Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outlook Quality of Life Intervention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with~* Advanced cancer~* Congestive heart failure~* COPD~* End stage renal disease~Exclusion Criteria:~* Cognitive impairment~* inability to speak~* non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Outlook Intervention (Type: EXPERIMENTAL): Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy.
- Attention Control (Type: ACTIVE_COMPARATOR): The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD.
- Treatment as Usual (Type: NO_INTERVENTION): Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Levosimendan on Microcirculation in Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Septic shock~* Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg)~Exclusion Criteria:~* Pregnancy~* Age \< 18 years~* Ventricular outflow tract obstruction~* Mitral valve systolic anterior motion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- levosimendan (Type: EXPERIMENTAL): None
- Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Permanent diabetes due to a mutation in KCNJ11 (KIR6.2)~* Patients successfully transferred from insulin to sulfonylurea~* Transferred to sulfonylurea treatment before November 1, 2006 (ie 9 years off insulin)~* Willing and able to provide informed consent (parents if younger than 16 years of age)~Exclusion Criteria:~* Permanent diabetes not due to a mutation in KCNJ11 (KIR6.2)~* Patients not successfully transferred from insulin to sulfonylurea~* Transferred to sulfonylurea treatment after November 1, 2006 (ie less than 9 years off insulin)~* Not willing or able to provide informed consent (parents if younger than 16 years of age)

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Sulfonylurea (Type: EXPERIMENTAL): Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected children~* Weight over 12 kgs~* Age over 30 months~* Clinical stage requiring HAART~* Naive to antiretroviral treatment (except PMTCT prophylaxis)~* Mother's or tutor's informed consent signed~Exclusion Criteria:~* HIV-2 or dual HIV infection~* Previous antiretroviral therapy~* Children unable to swallow pills~* Known resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI)

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete